Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI
Launched by NATIONAL INSTITUTE OF CARDIOLOGY, WARSAW, POLAND · Mar 10, 2025
Trial Information
Current as of May 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The ADRENALINE trial is a research study that aims to compare two different methods for treating a specific type of heart problem called chronic total occlusion (CTO), where a coronary artery is completely blocked. The two methods being compared are called antegrade dissection and re-entry (ADR) and retrograde strategy. Researchers want to find out which method is quicker, safer, and more effective, and how these procedures affect the stress levels of the doctors performing them. They will also look at whether the retrograde method leads to more heart damage compared to ADR.
To participate in this trial, individuals must be aged 65 or older and have certain heart conditions, such as chest pain or documented heart issues that require treatment for a difficult blockage in their coronary arteries. Participants will undergo various tests before and after the procedure to monitor their heart health and overall well-being. It’s important to know that potential participants will need to give their consent and that certain health conditions, like severe heart disease or recent heart attack, may disqualify them from the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
- • at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography
- • angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
- • informed consent for participation in the study
- Exclusion Criteria:
- • \<18 years of age
- • acute myocardial infarction
- • cardiogenic shock
- • severe valvular disease
- • estimated life expectancy \<1 year
- • contraindication to PCI
- • contrast allergy
- • positive pregnancy test or breast-feeding
- • native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \<2 points)
- • lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators
About National Institute Of Cardiology, Warsaw, Poland
The National Institute of Cardiology in Warsaw, Poland, is a leading research institution dedicated to advancing the understanding and treatment of cardiovascular diseases. Renowned for its commitment to innovative clinical research, the Institute focuses on improving patient outcomes through comprehensive studies that encompass prevention, diagnosis, and therapeutic strategies. With a multidisciplinary team of experts and state-of-the-art facilities, the National Institute of Cardiology plays a pivotal role in contributing to global cardiovascular knowledge and enhancing clinical practices in the field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warsaw, , Poland
Patients applied
Trial Officials
Maksymilian Opolski
Principal Investigator
National Institute of Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported